CFD 属于复杂的高风险金融工具，其杠杆作用可能导致投资者迅速亏损。 84% 的散户投资者因进行 CFD 交易遭受资金损失。 请您谨慎考虑自己是否了解 CFD 操作，以及是否能够接受高额亏损的风险。
Capital Com Australia Pty Ltd Australia (受监管于 ASIC) Capital Com UK Limited 受监管于 Financial Conduct Authority (FCA) Capital Com SV Investments Limited Cyprus / EU (受监管于 CYSEC) Сlosed Joint Stock Company «FinTech Solutions» (受监管于 NBRB) Smart Forex Broker LLC Capital Com Stock and CFD Investing Ltd Seychelles (受监管于 FSA) Capital Com Online Investments Ltd (受监管于 SCB) Our Global Offices

Scan to Download iOS&Android APP

English العَرَبِيَّة Bahasa Indonesia Български Čeština Dansk Deutsch Eesti ελληνικά Español Français Hrvatski Italiano Latviešu Lietuvių Magyar Nederlands Polski Português Română Русский Slovenčina Slovenščina Suomi Svenska Tiếng Việt ไทย 简体中文 繁體中文
您也可以联系我们： 致电 +44 2030978888 support@capital.com

交易 Cerevel Therapeutics Holdings, Inc. - CERE CFD

26.95
0.04%
  • 概括
  • 历史数据
  • 活动
  • 收入报表
  • 资产负债表
  • 现金流
  • 所有权
交易条件
价差 0.11
多头隔夜费

Long position overnight fee

Margin. Your investment $1,000.00
隔夜费用 -0.024068 %
Charges from borrowed part ($-0.96)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00
前往平台
-0.024068%
空头隔夜费

Short position overnight fee

Margin. Your investment $1,000.00
隔夜费用 0.001846 %
Charges from borrowed part ($0.07)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00
前往平台
0.001846%
隔夜费时间 21:00 (UTC)
最小交易量 1
货币 USD
保证金 20%
上市交易所 United States of America
交易费 0%

*Information provided by Capital.com

关键数据
前收盘价* 26.94
开盘价* 25.72
1 年变化* -4.56%
日范围* 25.72 - 27.24
52 周范围 19.86-41.46
平均交易量（10 天） 830.10K
平均交易量（3 个月) 12.64M
市值 3.67B
市盈率 -100.00K
流通股 156.66M
收入 N/A
EPS -2.32
股息（收益率 %） N/A
贝塔 -100.00K
下一个财报发布日期 May 8, 2023

所有数据都是由Refinitiv提供的， 除了标有星号的数据， 这是*由 Capital.com 提供的数据

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date 平倉 Change Change (%) 開倉 High Low
Jun 29, 2022 26.95 1.81 7.20% 25.14 27.30 25.14
Jun 28, 2022 26.94 -0.93 -3.34% 27.87 29.13 26.80
Jun 27, 2022 28.99 0.89 3.17% 28.10 29.70 27.49
Jun 24, 2022 28.08 -0.17 -0.60% 28.25 29.09 27.63
Jun 23, 2022 28.54 3.28 12.98% 25.26 28.60 25.26
Jun 22, 2022 26.05 1.34 5.42% 24.71 26.24 24.71
Jun 21, 2022 25.15 -0.32 -1.26% 25.47 25.47 24.03
Jun 17, 2022 23.86 0.20 0.85% 23.66 24.42 23.16
Jun 16, 2022 22.85 -1.18 -4.91% 24.03 24.03 22.07
Jun 15, 2022 24.53 0.31 1.28% 24.22 24.87 23.33
Jun 14, 2022 24.22 0.64 2.71% 23.58 25.12 23.54
Jun 13, 2022 23.87 -0.71 -2.89% 24.58 24.67 23.20
Jun 10, 2022 25.82 -0.27 -1.03% 26.09 27.04 25.60
Jun 9, 2022 27.99 0.51 1.86% 27.48 28.92 27.48
Jun 8, 2022 28.49 1.30 4.78% 27.19 29.41 27.19
Jun 7, 2022 28.72 3.24 12.72% 25.48 28.84 25.48
Jun 6, 2022 25.86 -1.88 -6.78% 27.74 28.32 25.13
Jun 3, 2022 27.78 1.02 3.81% 26.76 28.51 26.76
Jun 2, 2022 26.98 1.06 4.09% 25.92 27.80 25.30
Jun 1, 2022 26.37 0.40 1.54% 25.97 26.76 25.02

Cerevel Therapeutics Holdings, Inc. Events

時間（協調世界時） (UTC) 國家 事件
No events scheduled
查看所有活動
  • 年度
  • 每季度
2021 2020 2019
总收入 0 0 0
营业收入 -220.098 -149.116 0
摊薄调整 0
摊薄净收入 -225.334 -148.271 0
总营业费用 220.098 149.116
销售/一般/行政费用，总计 58.243 45.813
研究与开发 161.855 103.303
利息收入（费用），非经营净值 0.157 0.224
其他，净值 -5.393 -3.274
税前净收入 -225.334 -152.166
税后净收入 -225.334 -152.142
未计算非常项目前的净收益 -225.334 -152.142
净收入 -225.334 -152.142
Total Adjustments to Net Income 0 3.871
普通股股东可获收益 (不含非经常性项目) -225.334 -148.271
普通股股东可获收益 (含非經常性項目) -225.334 -148.271
摊薄后加权平均股 136.577 73.6433
扣除特别项目的每股摊薄盈利 -1.64987 -2.01337
每股正常摊薄盈利 -1.64987 -2.01337
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
总收入 0 0 0 0 0
总营业费用 72.53 64.49 54.527 50.51 50.571
销售/一般/行政费用，总计 17.507 16.649 14.368 13.216 14.01
研究与开发 55.023 47.841 40.159 37.294 36.561
营业收入 -72.53 -64.49 -54.527 -50.51 -50.571
利息收入（费用），非经营净值 0.295 0.119 0.013 0.01 0.015
其他，净值 3.941 5.316 -7.545 -2.739 -0.425
税前净收入 -68.294 -59.055 -62.059 -53.239 -50.981
税后净收入 -68.294 -59.055 -62.059 -53.239 -50.981
未计算非常项目前的净收益 -68.294 -59.055 -62.059 -53.239 -50.981
净收入 -68.294 -59.055 -62.059 -53.239 -50.981
普通股股东可获收益 (不含非经常性项目) -68.294 -59.055 -62.059 -53.239 -50.981
普通股股东可获收益 (含非經常性項目) -68.294 -59.055 -62.059 -53.239 -50.981
摊薄净收入 -68.294 -59.055 -62.059 -53.239 -50.981
摊薄后加权平均股 147.985 147.392 144.022 127.482 127.226
扣除特别项目的每股摊薄盈利 -0.46149 -0.40067 -0.4309 -0.41762 -0.40071
Dividends per Share - Common Stock Primary Issue 0 0 0 0
每股正常摊薄盈利 -0.46149 -0.40067 -0.4309 -0.41762 -0.40071
  • 年度
  • 每季度
2021 2020 2019
流动资产总额 578.017 390.56
现金和短期投资 565.688 383.623
现金等价物 193.018 383.623
Prepaid Expenses 11.6 6.777
Other Current Assets, Total 0.729 0.16
Total Assets 688.919 445.273
Property/Plant/Equipment, Total - Net 51.7 48.624
Property/Plant/Equipment, Total - Gross 54.266 48.706
Accumulated Depreciation, Total -2.566 -0.082
Other Long Term Assets, Total 6.933 6.089
Total Current Liabilities 42.538 29.548
Accounts Payable 11.298 4.993
Accrued Expenses 30.865 24.282
Notes Payable/Short Term Debt 0 0
Other Current Liabilities, Total 0.375 0.273
Total Liabilities 110.19 60.753
Total Long Term Debt 33.54 0
Other Liabilities, Total 34.112 31.205
Total Equity 578.729 384.52
Common Stock 0.015 0.013
Additional Paid-In Capital 1195.94 775.417
Retained Earnings (Accumulated Deficit) -616.244 -390.91
Total Liabilities & Shareholders’ Equity 688.919 445.273
Total Common Shares Outstanding 147.72 127.124
短期投资 372.67
Long Term Investments 52.269
Long Term Debt 33.54
Other Equity, Total -0.986
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
流动资产总额 553.55 578.017 675.029 331.782 349.811
现金和短期投资 542.944 565.688 669.676 327.06 343.287
现金等价物 91.764 193.018 669.676 327.06 343.287
Prepaid Expenses 10.004 11.6 5.257 4.597 6.362
Other Current Assets, Total 0.602 0.729 0.096 0.125 0.162
Total Assets 618.552 688.919 733.48 391.004 408.104
Property/Plant/Equipment, Total - Net 52.663 51.7 51.98 51.92 51.784
Property/Plant/Equipment, Total - Gross 56.299 54.266 53.526 52.552 51.876
Accumulated Depreciation, Total -3.636 -2.566 -1.546 -0.632 -0.092
Other Long Term Assets, Total 4.411 6.933 6.471 7.302 6.509
Total Current Liabilities 35.318 42.538 30.8 29.257 34.151
Accounts Payable 8.183 11.298 5.445 4.986 7.755
Accrued Expenses 26.442 30.865 24.928 23.939 26.241
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0.693 0.375 0.427 0.332 0.155
Total Liabilities 97.053 110.19 104.4 97.117 68.068
Total Long Term Debt 28.324 33.54 38.612 32.242 0
Other Liabilities, Total 33.411 34.112 34.988 35.618 33.917
Total Equity 521.499 578.729 629.08 293.887 340.036
Common Stock 0.015 0.015 0.015 0.013 0.013
Additional Paid-In Capital 1207.36 1195.94 1186.79 789.004 781.914
Retained Earnings (Accumulated Deficit) -684.538 -616.244 -557.189 -495.13 -441.891
Total Liabilities & Shareholders’ Equity 618.552 688.919 733.48 391.004 408.104
Total Common Shares Outstanding 148.183 147.72 147.136 127.585 127.325
Long Term Debt 28.324 33.54 38.612 32.242
Other Equity, Total -1.334 -0.986 -0.533
短期投资 451.18 372.67
Long Term Investments 7.928 52.269
  • 年度
  • 每季度
2021 2020 2019
净收入/起跑线 -225.334 -152.142
经营活动产生的现金 -178.546 -117.802
经营活动产生的现金 2.731 0.397
非现金物品 28.516 16.236
营运资金的变化 15.541 17.707
投资活动产生的现金 -435.661 -18.892
资本支出 -10.503 -18.892
融资活动产生的现金 423.602 440.835
融资现金流项目 -0.355 440.835
现金净变化 -190.605 304.141
其他投资现金流量项目，总计 -425.158
股票的发行（报废），净额 392.707
债务的发行（退还），净额 31.25
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Net income/Starting Line -68.294 -225.334 -166.279 -104.22 -50.981
Cash From Operating Activities -67.648 -178.546 -125.802 -82.026 -36.418
Cash From Operating Activities 1.118 2.731 1.644 0.664 0.063
Non-Cash Items 4.935 28.516 27.551 14.084 6.377
Changes in Working Capital -5.407 15.541 11.282 7.446 8.123
Cash From Investing Activities -38.542 -435.661 -9.431 -8.243 -4.66
Capital Expenditures -2.197 -10.503 -9.431 -8.243 -4.66
Cash From Financing Activities 2.603 423.602 421.286 33.706 0.742
Issuance (Retirement) of Stock, Net 2.854 392.707 390.036 2.571 0.742
Net Change in Cash -103.587 -190.605 286.053 -56.563 -40.336
Financing Cash Flow Items -0.251 -0.355 0 -0.115
Issuance (Retirement) of Debt, Net 31.25 31.25 31.25
Other Investing Cash Flow Items, Total -36.345 -425.158
投资者名称 投资者类型 流通股百分比 持有股份 股份变动 持有日期 换手率
Bain Capital Private Equity, LP Private Equity 38.704 60632356 0 2022-12-31 LOW
Pfizer Inc Corporation 17.4581 27349211 0 2022-08-16 MED
Fidelity Management & Research Company LLC Investment Advisor 14.5879 22852917 67107 2022-12-31 LOW
Perceptive Advisors LLC Private Equity 4.1567 6511727 0 2022-12-31 MED
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 3.8476 6027510 164460 2022-12-31 LOW
T. Rowe Price Associates, Inc. Investment Advisor 3.027 4742044 1202 2022-12-31 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 2.2049 3454078 288570 2022-12-31 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 2.1858 3424220 704948 2022-12-31 LOW
Federated Hermes Global Investment Management Corp. Investment Advisor/Hedge Fund 1.8304 2867451 -445882 2022-12-31 LOW
Rock Springs Capital Management LP Hedge Fund 1.6 2506464 7316 2022-12-31 LOW
T. Rowe Price Investment Management, Inc. Investment Advisor 1.2806 2006068 4631 2022-12-31 MED
Invus Public Equities Advisors, LLC Investment Advisor 1.2128 1900000 -100000 2022-12-31 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.7686 1204108 69847 2022-12-31 LOW
Janus Henderson Investors Investment Advisor/Hedge Fund 0.7349 1151321 -231639 2022-12-31 LOW
Lord, Abbett & Co. LLC Investment Advisor 0.7159 1121566 35610 2022-12-31 MED
Hood River Capital Management LLC Investment Advisor 0.5896 923638 27066 2022-12-31 MED
Alkeon Capital Management LLC Investment Advisor/Hedge Fund 0.5716 895509 -87899 2022-12-31 LOW
BlackRock Financial Management, Inc. Investment Advisor/Hedge Fund 0.4755 744853 7881 2022-12-31 LOW
Novalis LifeSciences LLC Private Equity 0.4043 633350 0 2022-03-31
Fidelity Institutional Asset Management Investment Advisor 0.3602 564215 34460 2022-12-31 LOW

为什么选择 Capital.com？让我们的数字来说话。

Capital.com Group

500K+

交易者

92K+

每月活跃客户

$53M+

每月投资额

$30M+

每月提取金额

交易計算器

如果您在特定日期（选择一个日期）开立差价合约交易并在不同日期（选择一个日期）关闭交易，计算您的假设盈亏。

貿易佣金
0
  • 1:1
杠杆
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
投資
交易規模（槓桿 x 投資）：
開倉

平倉

做空 做多
過去的表現並不是未來結果的可靠指標
盈利/失利

Cerevel Therapeutics Holdings, Inc. Company profile

关于 Cerevel Therapeutics Holdings Inc.

Cerevel Therapeutics Holdings, Inc.是一家处于临床阶段的生物制药公司。 公司将对疾病相关生物学和大脑神经回路的理解与化学和中枢神经系统（CNS）、受体药理学相结合，发现和设计新疗法。 公司正在从事神经科学疾病的新疗法的开发，包括精神分裂症、癫痫和帕金森病。 公司的候选产品包括CVL-231、Darigabat、Tavapadon、CVL-871和CVL-936。 公司的候选产品CVL-231用于治疗精神分裂症。 其Darigabat用于治疗癫痫和焦虑症。 其Tavapadon是一种多巴胺D1/D5部分激动剂，用于治疗早期和晚期帕金森病。 其候选产品CVL-871用于治疗痴呆症相关的冷漠症。 其CVL-936用于治疗物质使用障碍（SUD）。

Industry: Bio Therapeutic Drugs

222 Jacobs Street
Suite 200
CAMBRIDGE
MASSACHUSETTS 02141
US

收入报表

  • Annual
  • Quarterly

人们也观看

Oil - Crude

69.28 Price
-0.330% 1D Chg, %
多头隔夜费 -0.0194%
空头隔夜费 -0.0025%
隔夜费时间 21:00 (UTC)
价差 0.03

Gold

1,978.85 Price
-0.760% 1D Chg, %
多头隔夜费 -0.0179%
空头隔夜费 0.0097%
隔夜费时间 21:00 (UTC)
价差 0.30

US100

12,798.80 Price
+0.420% 1D Chg, %
多头隔夜费 -0.0241%
空头隔夜费 0.0018%
隔夜费时间 21:00 (UTC)
价差 3.0

XRP/USD

0.45 Price
-0.830% 1D Chg, %
多头隔夜费 -0.0753%
空头隔夜费 0.0069%
隔夜费时间 21:00 (UTC)
价差 0.00355

还在找一位您可以信任的经纪商吗？

加入成为全球500,000万多名交易者的一份子，选择利用Capital.com进行交易吧。

1. 创建和验证您的账户 2. 进行存款 3. 找到适合您的交易